IMPEDIMED LIMITED — Capital/Financing Update 2019

Jul 18, 2019

==> picture [230 x 54] intentionally omitted <==

19 July 2019

ASX ANNOUNCEMENT

COMPLETION OF ENTITLEMENT OFFER

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) ( ImpediMed or the Company ), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces the completion of its fully underwritten non-renounceable entitlement offer, ( Entitlement Offer ), which opened on 5 July 2019.

Under the Entitlement Offer, eligible shareholders were invited to subscribe for 1 new share ( New Share ) for every 3 shares in the Company of which they were the registered holder as at 7.00pm (AEST) on 2 July 2019, at an issue price of A$0.11 per New Share. The Entitlement Offer closed on 16 July 2019.

In accordance with the ASX Listing Rules, ImpediMed advises that it received valid applications under the Entitlement Offer for approximately 88,249,289 New Shares in ImpediMed (to raise approximately A$9.7 million).

The balance of 38,353,639 New Shares, being shares not subscribed for by eligible shareholders in accordance with their pro rata entitlements under the Entitlement Offer, will be issued under the underwriting arrangements described in the Offer Booklet.

The Entitlement Offer will raise approximately A$13.9 million (before costs and expenses).

New Shares are expected to be issued on Wednesday, 24 July 2019 and are expected to commence trading on a normal settlement basis on ASX on Thursday, 25 July 2019.

Contact details

Richard Carreon Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.